臨床泌尿器科59巻5号

2005年04月発行

綜説

局所進行性前立腺癌に対する根治的体外照射における内分泌療法の役割

著者： 頴川晋¹

所属機関： ¹東京慈恵会医科大学泌尿器科

ページ範囲：P.267 - P.272

文献概要

要旨　昨今の診断・治療法の進歩により，腺内限局性早期前立腺癌の治療オプションは広がり，治療成績も向上した。しかし，骨にまで広がった前立腺癌は内分泌療法によるコントロールを期待するしかないというのが現時点のコンセンサスである。これらの中間群，すなわち微小転移ないしは前立腺周囲のみの浸潤癌を，何らかの工夫によりある程度制御できるのではないかというのが最近の考え方であり，過去の数々の検討の命題であった。本稿では，特に「根治照射および内分泌療法併用」という治療戦略につき概説する。

参考文献

1）Egawa S, Suyama K, Arai Y, et al：Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol 8：295-300, 2001

2）Egawa S, Suyama K, Arai T, et al：A study on pretreatment nomogram to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J Clin Oncol 31：74-81, 2001

3）Partin A, Piantadosi S, Sanda M, et al：Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45：831-838, 1995

4）Pisansky T, Kahn M and Bostwick D：An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 79：2154-2161, 1997

5）Kattan M, Zelefsky M, Kupelian P, et al：Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18：3352-3359, 2000

6）D'Amico A, Whittington R, Malkowicz S, et al：Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280：969-974, 1998

7）Sebo T, Bock B, Cheville J, et al：The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163：174-178, 2000

8）Roach M, Lu J, Pilepich MV, et al：Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys 47：609-615, 2000

9）Green N, Melbye R, Lipsett J, et al：Measures to improve therapeutic response and prevent complication. Urology 3：287-290, 1975

10）van der Werf-Messing B：Prostatic cancer treated at the Rotterdam Radiotherapy Institute. Strahlentherapie 154：537-541, 1978

11）Green N, Bodner H, Broth E, et al：Response of lymph node metastasis to sequential estrogen and radiation therapy in prostate carcinoma. Urology 18：137-142, 1981

12）Green N, Chang C, Goldberg H, et al：Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 10：971-976, 1984

13）Kramolowsky E：The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 139：1242-1244, 1988

14）Pilepich MV, Krall JM, John J, et al：Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy：preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys 16：813-817, 1989

15）Pilepich MV, Caplan R, Byhardt RW, et al：PhaseⅢ trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy：report of RTOG 85-31. J Clin Oncol 15：1013-1021, 1997

16）Pilepich M, Winter K, Lawton C, et al：PhaseⅢ trial of androgen suppression adjuvant to definitive radiotherapy：long term results of RTOG study 85-31. J Clin Oncol 22：281, 2003

17）Lawton CA, Winter K, Murray K, et al：Updated results of the phaseⅢ RTOG trial 85-31. Evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radial Oncol Biol Phys 49：937-946, 2001

18）Bolla M, Gonzalez D, Warde P, et al：Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337：295-300, 1997

19）Bolla M, Collette L, Blank L, et al：Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer（an EORTC study）. Lancet 360：103-106, 2002

20）Bolla M, Collette L, Gonzalez D, et al：Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy：a phaseⅢ EORTC study. Proceedings of the 41st Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys 45：147, 1999

21）Pilepich MV, Krall JM, Al-Sarraf M, et al：Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma：a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45：616-623, 1995

22）Pilepich M, Winter K, John M, et al：PhaseⅢ radiation therapy oncology group（RTOG）trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50：1243-1252, 2001

23）Hanks GE, Pajak TF, Porter A, et al：PhaseⅢ trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate：the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21：3972-3978, 2003

24）Roach M, DeSilvio M, Lawton C, et al：PhaseⅢ trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol 21：1904-1911, 2003

25）D'Amico AV, Manola J, Loffredo M, et al：6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 292：821-827, 2004

26）Hanks G, Hanlon A, Pinover W, et al：Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46：823-832, 2000

27）Pollack A and Zagars G：External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39：1011-1018, 1997

28）Hanks G, Hanlon A, Pinover W, et al：Survival advantage for prostate cancer patients treated with high dose 3D conformal radiation. Cancer J Sci Am 5：152-158, 1999

29）Fellows GJ, Clark PB, Beynon LL, et al：Treatment of advanced localized prostatic cancer by orchiectomy, radiotherapy, or combined treatment：a Medical Research Council study. Urological Cancer Working Party-Subgroup on Prostatic Cancer. Br J Urol 70：304-309, 1992

30）Mason MD, Brewster S, Moffat LE, et al：MRC PR07 Trial Management Group. Randomized Trials in Early Prostate Cancer. Ⅱ：Hormone therapy and radiotherapy for locally advanced disease：a question is still unanswered. Clin Oncol 12：215-216, 2000